Objectives: Determining the prevalence of multiple cardiometabolic risk (CMR) factors requires clinical and laboratory data not readily available to most health-care plans. We evaluated the ability of a simple model derived from the National Health and Nutrition Examination Survey (NHANES) using commonly available demographic information to predict prevalence of multiple CMR factors. Methods: We defined CMR factors according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and International Diabetes Federation (IDF) guidelines for metabolic syndrome classification in both the Atherosclerosis Risk in Communities (ARIC) and the Framingham Offspring Study (FOS) cohorts. Using NHANES data, a simple demographic model consisting of sex, race and ethnicity, smoking status, and the natural logarithm of age, generated the coefficients used to predict the prevalence of multiple CMR factors in ARIC and FOS. Predicted prevalences were compared with the observed prevalences in both cohorts. Results: The ARIC and FOS cohorts consisted of 11,596 and 3532 subjects with a mean age of 62.6 and 58.8 years, respectively. The observed proportion of participants with metabolic syndrome in ARIC was 52.1% and 58.8% according to the NCEP and IDF definitions, respectively. In FOS the observed prevalence was 41.4% and 45.8% using the NCEP and IDF definitions. Predicted prevalences of metabolic syndrome for the NCEP and IDF definitions, respectively, were 51.3% and 53.5% in ARIC, and 48.2% and 51.4% in FOS. Differences between the observed and predicted prevalences for three of four additional risk factor sets, including abdominal obesity (AO) alone, AO plus diabetes, and AO plus diabetes plus dyslipidemia, were small (between 1 to 7 percentage points) in both cohorts. The model poorly predicted the prevalence of AO plus dyslipidemia. Conclusion: A simple demographic model adequately predicted the prevalence of CMR factors. The model should help health-care plans lacking clinical and laboratory data to estimate prevalence of CMR factors in their populations. Future studies need to evaluate the influence of race, sex, and ethnicity on prevalence of these risk factors in various settings.
Introduction
Cardiometabolic risk (CMR) factors, including obesity, dyslipidemia, hypertension, and insulin resistance, are health conditions known to increase the risk of cardiovascular disease. A major public health concern is the high prevalence of these risk factors among US adults, aged 20 years and older. In 2004, the prevalence of obesity was estimated to be 32.9% among US adults, aged 20 to 74 years [1] . Based on the National Health and Nutrition Examination Survey (NHANES) III data, the estimated prevalence of dyslipidemia among US adults aged 20 years and older was 35.6% [2] . During 1999 to 2002, the estimated prevalence of hypertension was 28.6% among US adults aged 20 years and older [3] . Insulin resistance, by either evidenced impaired fasting glucose (IFG) or diabetes, is also high. In 2005, the estimated prevalence of total diabetes was 9.6% among US adults aged 20 years and older, and 20.9% among US adults aged 60 years and older [4] .
The population at risk for vascular disease, and especially for diabetes, includes patients with IFG, which has an estimated prevalence of 26% in adults aged 20 years and older [5] . An alarming observation is that IFG generally increases with age, peaking at 39.1% in the elderly population aged 65 years and older [5] . This age group is of particular concern because it is the most rapidly growing population segment [6] and, in 2004, contained almost 40% of the diabetic population in the United States [7] . In the US population, the proportion of diabetics who are elderly is projected to increase to 58% by 2050 [8] .
The relationship between each risk factor and cardiovascular disease is complex, and is complicated further by the relationships the risk factors have with each other. Some researchers suggest that the presence of multiple CMR factors increases the risk for developing cardiovascular disease, with relative risks for arteriosclerotic cardiovascular disease between 1.4 and 4.3, depending on vascular outcomes and risk factor burden [9] [10] [11] [12] [13] [14] [15] [16] [17] . Studies demonstrate that non-diabetics with cardiometabolic risk factors have at least twice the risk of developing type 2 diabetes as those without cardiometabolic risk factors [18] [19] [20] [21] . Finally, as the number of cardiometabolic risk factors increases, the risk of cardiovascular disease accelerates in non-diabetics [20] .
Whether the presence of multiple CMR factors can be classified as a unique syndrome is now a topic of debate [22] [23] [24] . Risk factors associated with various degrees of morbidity and the development of costly sequelae are obesity, and perhaps a more refined definition of increased waist circumference with elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, elevated fasting glucose, and elevated blood pressure or hypertension. Whether we consider each factor alone or in combination, the result is a patient population at high risk for devastating health consequences if not treated. The joint relationship between future risk of cardiovascular disease and increases in weight, glucose, and blood pressure, and lipid derangements warrants further investigation. At a minimum these risk factors do appear to cluster and are associated with significant morbidity. A critical first step is raising awareness of the prevalence of these risk factor in various health-care settings.
Until recently, determining the presence of CMR clusters required clinical and laboratory data not readily available to most health-care plans. Now Hollenbeak et al. [submitted] have developed a model and presented the possibility of accurately predicting the prevalence of CMR clusters using only simple demographic data. The research presented below sought to test whether Hollenbeak's model could accurately predict the prevalence of CMR clusters in two large and diverse observational studies, the Atherosclerosis Risk in Communities Study (ARIC) and the Framingham Offspring Study (FOS).
Methods

Data
We used two separate data sets to test the predictive equations developed by Hollenbeak et al. [submitted] , the ARIC-, and FOS. ARIC, a prospective study of four community sites in Maryland, Mississippi, Missouri, and North Carolina, was designed to study risk factors and the natural history of atherosclerosis and cardiovascular disease among an ethnically diverse cohort. A cohort of nearly 16,000 was examined at baseline (1987) and reexamined four times at 3-year intervals. Examinations included extensive laboratory tests and anthropometric assessments. In addition to periodic medical examinations at the center, yearly follow-up phone interviews were conducted by study staff to update the health status of each participant. Analyses presented here are restricted to examination 4, which was conducted between 1996 and 1998 (N = 11,596).
Framingham Offspring Study began in 1971 with the recruitment of 5124 men and women, consisting of offspring of participants in the original Framingham Heart Study. FOS participants have completed six regular physical examinations and surveys of lifestyle factors (including extensive laboratory tests and anthropometric examinations) at intervals of 4 to 6 years and have been followed for morbidity and mortality over that time period. Analyses presented here are restricted to examination 6, which was conducted between 1996 and 1999 (N = 3532).
We excluded individuals lacking data for any of the CMR factors of interest, leaving a study sample of 3222 and 11,000 adults in FOS and ARIC, respectively, for analyses.
Definitions of Risk Factors
Definitions of the six CMR factor sets are presented in Table 1 . Individuals with cardiovascular comorbidities were not excluded. The two data sets did not allow for uniform adherence to the cluster definitions in two instances: medications for triglycerides and evidence of previously diagnosed diabetes. ARIC is currently developing an indicator variable for antitriglyceride medications for its public-use data set; this indicator is available in FOS. For prior diabetes, ARIC provided age of onset, whereas FOS provided an indicator variable for whether one of two diabetes-diagnosing conditions was met: fasting plasma glucose greater than or equal to 126 mg/dL or self-report of taking antidiabetes medications. The risk factor definitions were applied to the data sets using the STATA statistical package, version 8.2 (StataCorp, College Station, TX, USA).
Observed and Predicted Prevalence
For each set of CMR factors, we computed an observed prevalence and 95% confidence interval as a simple binomial proportion using the SAS statistical package (version 9.1) (SAS Institute, Cary, NC, USA). We used the logistic regression models derived from the NHANES data set and developed by Hollenbeak et al.
[submitted] to obtain the predicted prevalence of each of the six sets. Specifically, we applied the coefficients from those regression models to score the data in ARIC and FOS, respectively, and produced the predicted prevalence as the mean of the individual predicted probabilities. Confidence intervals around the predicted prevalence point estimates were derived from a bias-corrected bootstrapping procedure using 1000 replicates. We repeated the procedure to assess how well the predicted prevalence matched the observed prevalence in three age strata: <55 years, 55 to 64 years, and >64 years. Table 2 presents the demographic and clinical characteristics of the two study populations. ARIC participants were older on average (mean age 62.6 year in ARIC vs. 58.8 year in FOS) and had a higher percentage of women (55.8% vs. 53.1%) than FOS participants. Also, the distribution of race varied (100% white in FOS compared with 77% in ARIC) and race varied ARIC participants had higher mean waist circumference, body mass index, fasting glucose and triglyceride values, and lower mean HDL and diastolic blood pressure. The prevalence of most of the CMR factors under study was higher among ARIC participants than among those in FOS (Table 3) .
Results
Although both systolic and diastolic blood pressure was higher among FOS participants, more ARIC participants were classified as having elevated blood pressure, having met the criteria because they had received treatment. Table 4 and Figure 1 show the observed and predicted prevalence of the six sets of CMR factors in the two cohorts. The table includes the demographic inputs for the prediction model (i.e., mean age, proportion of men, smokers, and race) for each cohort. For the five risk factor sets other than abdominal obesity (AO) plus dyslipidemia, the differences between the observed and predicted prevalence range from 0.8% to 6.8%. The predictive ability of the model for the AO plus dyslipidemia risk factor set is poor in both populations (differences of 21.9% and 11.7% in ARIC and FOS, respectively). For the five other sets, differences between the observed and predicted prevalence in ARIC are within two percentage points for three sets and just more than five percentage points for the other two. In FOS, differences in two risk factor sets are within two percentage points, and differences for the other three are within seven percentage points. The 95% confidence intervals derived from the bootstrapping procedures for the predicted prevalence estimates do not include the observed point prevalence.
The observed and predicted prevalence of the six sets of CMR factors in three age groups (<55 years, 55-64 years, and >64 years) across the two cohorts are shown in Table 5 and includes the demographic inputs for the prediction model (i.e., mean age, and proportion of men, smokers, and race) for each population subset. The differences between observed and predicted values are, again, higher in the set including AO and dyslipidemia. In ARIC, differences between the observed and predicted prevalence do not vary systematically with age group, whereas the prediction model usually performs better in the 55 to 64 years age range in FOS compared with the younger (<55) FOS group. When the AO plus dyslipidemia set is excluded, the differences between the observed and predicted prevalence in ARIC are within five percentage points for 13 of the 15 sets across the age strata, and the remaining two are within six percentage points. Differences between the observed and predicted prevalence are within five percentage points in 10 of the 15 sets (excluding AO plus dyslipidemia) across the age strata in FOS. In the younger age group (<55 years) in FOS, differences between the observed and predicted prevalence are within 10 percentage points in four sets and within five percentage points in two of those.
Discussion
In this study, population characteristics commonly available to health-care plans predicted the prevalence of different sets of CMR factors in both the ARIC and FOS cohorts. these factors, the NCEP Adult Treatment Plan (ATP) III published criteria for metabolic syndrome, which combines these risk factors. The International Diabetes Federation (IDF) also published guidelines for classifying subjects with this constellation of risk factors, although the criteria differed in that a person had to have central obesity as an entry criterion; furthermore, the IDF definition included subjects who were treated for hypertriglyceridemia or low HDL cholesterol. As a result, these definitions provide different prevalence estimates. In NHANES, Ford reported a prevalence of 34.5% using the NCEP definition and 39% using the IDF definition [25] . We found similar differences in FOS, where the NCEP and IDF definitions yielded prevalence estimates of 41.4% and 45.8%, respectively. The prevalence estimates in ARIC were similar to those for FOS, and estimates were higher with the IDF definition compared with the NCEP definition. The differences are explained in part by the inclusion of the treatment variables in the IDF definition. Also differences are in part explained by demographic differences between the subjects in both databases com- pared with the demographics of the subjects in the database used for the development of the prediction model. Either definition leads to slightly different prevalence estimates that also vary with the population base. This variation is to be expected as the baseline populations differ. For example, the ARIC cohort population is slightly older, has a greater average waist circumference, and has a greater number of people treated for hypertension than the FOS cohort. In addition, the mean age in both cohorts is greater compared with the NHANES sample (data not shown). Ford reported an overall prevalence of metabolic syndrome based on the IDF definition of 39% using a sample of people from across the United States. In contrast, we report a prevalence of 58.8% in the ARIC cohort and 45.8% in the FOS using the IDF definition. Our results illustrate the differences in the base populations and demonstrate the need to assess prevalence across various cohorts. One likely explanation for these differences is the higher mean age in both ARIC and FOS compared with the NHANES survey. Advancing age is associated with a greater prevalence of the risk factor clusters. As illustrated in Table 5 , the difference in the proportion of subjects with metabolic syndrome among those older than age of 64 years compared with those younger than 55 years of age was 12% in ARIC, and 20% in FOS where the mean age in the youngest group is 48.6 years.
The study is limited because the model utilizes only factors readily available to most health-care plans. This, in part, explains the differences between the predicted and observed prevalence estimates. Another potential reason is that the cohorts are derived from data taken for years from 1996 to 1999, whereas the NHANES data are from 2001 to 2002. Treatment for dyslipidemia with Hmg_CoA reductase inhibitors likely increased, which would reduce triglycerides and increase HDL cholesterol. Treatment with statins is not considered in the model, so the model likely under- estimates the prevalence of multiple CMR factors. This results in an underestimation of dyslipidemia in both ARIC and FOS compared with the observed prevalence. The addition of a lipid value while accounting for lipid lowering treatments would likely improve the model and could be considered as a second tier screening prediction model. Prediction models that also include adjustments for other treatments that may alter the outcomes such as the use of ACE inhibitors as well as adherence to prescribed therapies would be of valued. Unfortunately, many of these variables are not readily available to most health-care plans but may in the future. Age is another key reason for the differences between the ARIC and FOS prevalence estimates. In Table 5 , the observed and predicted estimates are closer with advancing age, consistent with the fact that the risk factors increase with age. In the group <55 years of age, it is also important to note that the mean age in FOS is younger, which likely accounts for the lower observed prevalence. Further investigation evaluating how various characteristics account for differences in sets of multiple CMR factors across varying populations is needed and is planned for future analyses.
The advantage of this limited model is applicability over a wide range of uses, although in certain circumstances it may underestimate the true prevalence of CMR factors. Nevertheless, the addition of a single clinical variable such as weight or blood pressure would greatly enhance the accuracy of the model. The addition could be deployed easily as an initial screening evaluation and would dictate the need for additional laboratory testing. Many models include variables that are often collinear and that actually fail to provide any added value to the overall accuracy of the estimates. Such is not the case with the approach that we took.
As a simple tool for describing the potential at-risk population in health-care settings, Hollenbeak's demographic model provides a first step in assessing the occurrence of CMR factors. Knowing the prevalence of the CMR factors in their setting, health-care providers can begin to design and implement cost-effective and appropriate treatment programs that will result in improved health and economic outcomes.
